Author: Lynne Taylor

The European Medicines Agency (EMEA) Road Map to 2015 will be presented to the Agency’s Management Board this Thursday (December 10), and is expected to go out for public consultation in January, officials have said.

European biopharmaceutical companies’ existing problems in gaining access to funding have been worsened by the global financial crisis and, in the long term, this could force them to give up their drug development activities, warns a new report.

In a shock decision, pharmaceutical policy in the new European Commission will no longer be the responsibility of DG Enterprise and Industry but will move to the Health and Consumer Policy directorate, DG Sanco.

As new guidance on the standards required for communicating company-sponsored medical research is published, today on bmj.com two experts debate whether drug firms carrying out clinical trials on their own medicines creates an unacceptable conflict of interest.

US Senators are due to begin today what is likely to be a long and bruising debate on its controversial health care reform bill.